Navigation Links
Lighting the Onco-Pipeline, Stem Cell Cancer, and More at Global Cancer Congress, January 28-29, 2008, Tampa
Date:9/18/2007

NEW YORK, Sept. 18 /PRNewswire/ -- iiBIG is pleased to announce the never- before assembly of Global Cancer Experts at the 2008 Global Cancer Congress: Lighting the Onco-Pipeline -- Innovations in Stem Cell, Biomarker, Chemistry & Novel Therapeutic R&D, January 28-29, 2008 in Tampa, Florida. iiBIG is particularly pleased to join forces with our Florida affiliates from University of South Florida, University of Florida, Shands Cancer Center, Scripps Florida, and the other Florida cancer and academic institutes along with our nationally recognized distinguished faculty at this cutting-edge event.

This event will be the torchbearer to the most significant advances in cancer research, new therapies and novel approaches in the "War against Cancer". The program features a 2-track forum, with over 30 speakers, comprising plenary keynotes, lectures, panel sessions, roundtable discussions, interactive conversations with faculty and delegates, and actionable networking opportunities with leaders in various aspects of cancer research.

Distinguished Executive Speaking Faculty:

David L. Keefe, M.D.

James M. Ingram Professor and Chairman of the Department of Obstetrics and

Gynecology

University of South Florida

George Church, Ph.D.

Director of the Center for Computational Genetics, Director of the

Department of Genetics

Harvard-MIT Division of Health Sciences & Technology and Harvard Medical

School, Harvard University

William G. Thilly, Sc.D.

Professor of Biological Engineering

MIT

David J. Newman, Phil Sc.,

Chief, Natural Products Branch

National Cancer Institute (NCI)-FCRDC

James L. Sherley, M.D., Ph.D.

Senior Scientist

Regenerative Biology and Cancer Programs

Boston Biomedical Research Institute

Edward Scott, Ph.D.

Director of the UF Program in Stem Cell Biology and Regenerative Medicine

University of Florida

Gary D. Smith, Ph.D.,

Associate Professor, Departments of OB/GYN, Physiology, and Urology

Director: Reproductive Sciences Program, University of Michigan

James D. McChesney, Ph.D.,

CSO, Natural Products Chemistry

Tapestry Pharmaceuticals, Inc.

Tomi Sawyer, Ph.D.,

Senior Director, Department of Chemical Sciences

Pfizer Global R&D

Michael Nickerson

Director Genomic Research Division

Transgenomic Labs

Dalia Cohen, Ph.D.

Executive Vice President, Head of Global Research and Development

Rosetta Genomics, Ltd.

Gregg B. Fields, Ph.D.,

Professor and Chair, Department of Chemistry & Biochemistry

Florida Atlantic University

Chris Liang, Ph.D.

Scientific Director I, Translational Research Institute

Scripps Florida

Marilyn A. Apfel, Ph.D.

Co-founder and President

xFDA, LLC

Julia H. Riley, DVM, MS,

Diplomate American College Veterinary Pathologists, Diplomate American

Board Toxicology, Heads the Biologics Division, Toxicologist

xFDA, LLC

Ahsan Awan, JD, MBA,

Chief Executive Officers

Global CINRG, Inc.

Bernard Munos, Ph.D.,

Advisor, Corporate Strategy

Eli Lilly and Company

Stephen Chakoff

President & CEO

CHS Resources LLC

Jean-Claude Bystryn, M.D.

CEO & CSO

NeoVac

Glenn Batchelder

President and CEO

BIND Biosciences, Inc., latest Robert Langer, Ph.D. - MIT, Nanotechnology

Company

Christopher Milne, D.V.M., M.P.H., J.D.

Associate Director

Tufts Center for Drug Development

Mark Newman, Ph.D.

Senior Vice President, Global Research and Development Laboratories

Pharmexa-Epimmune

AGENDA TOPICS:

Some of the conference topics to be addressed (but are not limited to) include:

-- Integrative BioPharma Oncogenomics Standardizing Genetic Analysis

-- Drug Discovery Breakthroughs-Promising Compounds

-- Stem Cell Biology & Genetic Integrity

-- Interplay between Cancer & Stem Cells

-- Immunology

-- Micro-Tumor-Environment

-- Proteomic Biomarkers - Molecular Diagnostics: Earlier Detection and

Customizing Care

-- Therapeutic Vaccines Advancements

-- Multi-Drug Interaction - Drug Safety

-- Cancer Susceptibility, Resistance, and Systemic Changes

-- New Drugs Showing Real Promise

-- C-Team - Business Collaboration & Alliances between academia,

government, industry, foundations, regulatory, and private investment

resources - The Real Scenarios!

-- Biotech Showcase: Visit with 5 exciting young biotechnology companies*

in the cancer marketplace - The Real Light Makers

SPEAKING OPPORTUNITIES: Topic abstracts and speaker profiles will be accepted for consideration.

For more information, please contact Shelley Amster, VP, Pharmaceutical & Life Sciences Conferences, iiBIG, at 978-371-5901 or Shelleya@iibig.com.

SPONSORSHIP OPPORTUNITIES: For information on available sponsorship and exhibiting opportunities, please contact Kellie Swanstrom, VP Business Development, iiBIG, at 973-571-0867 or kellies@iibig.com.

FOR CONFERENCE UPDATES AND REGISTRATION INFORMATION:

Please visit: http://www.iibig.com/P0801

Call: 212-300-2523

E-mail: info@iibig.com


'/>"/>
SOURCE iiBIG
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Cooper Lighting picks RedPrairie solutions
2. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
3. The state of global biotech: An Ernst & Young perspective
4. Doyle announces new energy, global warming policies
5. Lucigen Corp. enters global licensing agreement
6. Global information firm reaches diverse markets
7. Work-life imbalance - A global problem getting worse
8. Leading global Big Pharma companies of 2005
9. Learning to swim in the global talent pool
10. Federal and global guidelines on stem cell research offer a level playing field
11. Midwest life-science company Perrigo globalizes under the radar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... SPRING, Md. , June 23, 2016 A ... collected from the crime scene to track the criminal down. ... and the U.S. Food and Drug Administration (FDA) uses DNA ... Sound far-fetched? It,s not. The ... genome sequencing to support investigations of foodborne illnesses. Put as ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology:
(Date:5/9/2016)... , UAE, May 9, 2016 ... it comes to expanding freedom for high net worth ... Even in today,s globally connected world, there is still ... system could ever duplicate sealing your deal with a ... second passports by taking advantage of citizenship via investment ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
Breaking Biology News(10 mins):